Frequently Asked Questions

Q. On which exchange is Regenicin's stock traded, and what is its ticker symbol?
A. Regenicin common stock is listed on the OTC under the symbol RGIN.OB.

Q. What is Regenicin's Mission Statement? A: Regenicin, Inc. (OTC Bulletin Board: RGIN.OB), is a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in the development of the therapeutic candidate, Regenicin cultured skin substitute, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of catastrophic burns.

Q. What is Regenicin's Business Model?
A: Regenicin's business model is to identify promising new therapeutic candidates that address unmet needs in growing markets; develop the most strategic, economical and expeditious pathways for achieving regulatory approval by the FDA; and to create a commercialization pipeline for bringing these new candidates to market once FDA approved.

Q. Where is Regenicin headquartered?
A. Company is headquartered in New Jersey.

Q. When is Regenicin's fiscal year-end?
A. Regenicin's fiscal year-end is September 30.